Flagship Pioneering Portfolio 2026

13 companies backed by Flagship Pioneering, including Inari, Lila Sciences, Harbinger Health. Each links to its full verified cap-table syndicate.

Flagship Pioneering accounts for 27 tracked companies with verified cap-table data, 27 of which disclose round sizes totalling $4.4B. The median disclosed raise is $120M, and the largest is Sana Biotechnology at $700M, ahead of Omega Therapeutics ($400M) and Sigilon Therapeutics ($363M).

The names that recur most often on these portfolio cap tables are Flagship Pioneering (27 companies), Altitude Life Science Ventures (3 companies), Canada Pension Plan Investment Board (2 companies), Alaska Permanent Fund (2 companies), BlackRock (2 companies), Stage 1 Ventures (2 companies). By latest disclosed round, the market skews Series A (7), Series B (5), Seed (4), Growth (3).

Best funded Flagship Pioneering companies

  1. Sana Biotechnology — $700M (latest: IPO)
  2. Omega Therapeutics — $400M (latest: IPO)
  3. Sigilon Therapeutics — $363M (latest: Growth)
  4. Cellarity — $274M (latest: Series C)
  5. Indigo — $250M (latest: Series F)
  6. Senda Biosciences — $226M (latest: Series C)
  7. Lila Sciences — $200M (latest: Seed)
  8. Dyne Therapeutics — $200M (latest: Series E)
  9. Harbinger Health — $190M (latest: Series B)
  10. Repertoire Immune Medicines — $189M (latest: Series B)
  11. Ampersand Biomedicines — $165M (latest: Series B)
  12. Alltrna — $159M (latest: Series B)
  13. Invaio Sciences — $142M (latest: Series C)
  14. Mirai Bio — $120M (latest: Series A)
  15. Ring Therapeutics — $117M (latest: Series B)

Flagship Pioneering Fund VIII General Partner LLC — related firms and companies (56)

Flagship Pioneering Fund VIII General Partner LLC profile · All research reports